Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1

Conditions

Multiple Myeloma 66Recurrence 20Neoplasms, Plasma Cell 8Primary Myelofibrosis 3Polycythemia Vera 3Myeloproliferative Disorders 3Renal Insufficiency 2Plasmacytoma 2Lymphoma, Non-Hodgkin 2Immunoglobulin Light-chain Amyloidosis 2Central Nervous System Neoplasms 2Waldenstrom Macroglobulinemia 1Unspecified Adult Solid Tumor, Protocol Specific 1Thrombocytosis 1Thrombocythemia, Essential 1Sarcoma, Kaposi 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Optic Nerve Glioma 1Neurofibromatosis 1 1Neoplasms 1Medulloblastoma 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell 1Leukemia, Plasma Cell 1Leukemia, Myeloid, Acute 1Leukemia, Megakaryoblastic, Acute 1Intraocular Lymphoma 1Hodgkin Disease 1Glioma 1

Interventions

fludarabine phosphate 6Peripheral Blood Stem Cell Transplantation 6Melphalan 6Whole-Body Irradiation 5Tacrolimus 5Mycophenolic Acid 5Dexamethasone 4Cyclophosphamide 4fludarabine 3filanesib 3Bortezomib 3ixazomib 2Steroids 2Sirolimus 2Lenalidomide 2Injections, Subcutaneous 2Granulocyte Colony-Stimulating Factor 2Filgrastim 2Etoposide 2Cytarabine 2Carmustine 2Antilymphocyte Serum 2pomalidomide 1merphos 1elotuzumab 1dexamethasone acetate 1dexamethasone 21-phosphate 1carmustine, poliferprosan 20 drug combination 1carfilzomib 1auricularum 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Leukemia, Plasma Cell × pomalidomide × Clear all
NCT02547662 2023-10-30

Pomalidomide, Ixazomib Citrate, and Dexamethasone in Treating Patients With Previously Treated Multiple Myeloma or Plasma Cell Leukemia

Mayo Clinic

Phase 2 Completed
17 enrolled 13 charts
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma, Plasmacytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡